NEW YORK, March 21, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc.
(NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX),
Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc.
(NASDAQ: OPXA). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at:
http://www.AnalystsReview.com/register http://www.analystsreview.com/register
http://www.analystsreview.com/register
Idenix Pharmaceuticals Inc. Analyst Notes
On March 14, 2014, Idenix
Pharmaceuticals Inc. (Idenix) announced that the Company has filed
patent infringement lawsuits against Gilead Sciences, Inc. (Gilead)
and/or certain of its subsidiaries in France, Germany, and the United Kingdom. Idenix informed that the
lawsuits allege that Gilead infringes the Company's
recently-granted, co-owned European patent EP 1 523 489 that covers
2'-methyl-2'-fluoro nucleosides for treating the hepatitis C virus.
Additionally, the Company stated that it is seeking remedies with
respect to Gilead's marketing and sales of drugs containing
sofosbuvir, which according to Idenix infringes the Company's
European patent. Commenting on the lawsuit, Maria Stahl, Senior Vice President and General
Counsel for Idenix, stated, "We are pleased to have been granted
this European patent, and today's filings further confirm Idenix's
conviction in the strength of our intellectual property portfolio
and the resolve we have to protect it. Idenix has invested
significant resources in nucleoside drug discovery and in building
a valuable intellectual property portfolio - and we will continue
to vigorously defend it. These proceedings, along with the U.S.
infringement actions we filed in December, are part of a concerted
effort to safeguard these technologies." The full analyst notes on
Idenix Pharmaceuticals Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03212014/IDIX/report.pdf
BG Medicine, Inc. Analyst Notes
On March 12, 2014, BG Medicine,
Inc. (BG Medicine) reported that it welcomes the announcement of
positive top-line results by La Jolla Pharmaceutical Company (LJPC)
on March 10, 2014 of its randomized,
placebo-controlled Phase 2 trial of the galectin-3 inhibitor
compound GCS-100 in chronic kidney disease. According to the
Company, the trial met its primary efficacy endpoint of improvement
in kidney function and key secondary endpoints which include a
statistically significant reduction in circulating levels of
galectin-3, at the effective therapeutic dose as measured using the
BGM Galectin-3® test (developed by BG Medicine). Commenting on the
results, Dr. Paul R. Sohmer,
President and CEO of BG Medicine, stated, "We welcome the important
clinical science that this Phase 2 trial represents. We look
forward to the continued advancement of the fundamental science on
the biological role of galectin-3 in health and disease." The full
analyst notes on BG Medicine, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03212014/BGMD/report.pdf
Progenics Pharmaceuticals Inc. Analyst Notes
On March 13, 2014, Progenics
Pharmaceuticals Inc. (Progenics) reported its Q4 2013 and full-year
2013 financial results. Q4 2013 total revenues decreased by 66.6%
YoY to c. $3.0 million, mainly due to
prior year partnering transactions, while full-year 2013 total
revenues declined by 44.0% YoY at $7.9
million. Net loss for Q4 2013 was $8.6 million or $0.14 loss per diluted share, compared to net
loss of $0.3 million or $0.01 loss per diluted share in Q4 2012. Net loss
for full year 2013 was $42.6 million
or $0.76 per diluted share, compared
to net loss of $35.4 million or
$1.02 per diluted share in full year
2012. The Company also announced that it is commencing clinical
development of MIP-1095, a PSMA-targeted small molecule
radiopharmaceutical for treating prostate cancer. The full analyst
notes on Progenics Pharmaceuticals Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03212014/PGNX/report.pdf
Omeros Corporation Analyst Notes
On March 18, 2014, Omeros
Corporation's (Omeros) stock went up by 10.59%, closing at
$12.74. Over the past six-month
trading session, Omeros' shares rose 75.71%, compared to the Nasdaq
Composite which gained 14.52% during the same six-month trading
session. The full analyst notes on Omeros Corporation are available
to download free of charge at:
http://www.AnalystsReview.com/03212014/OMER/report.pdf
Opexa Therapeutics, Inc. Analyst Notes
On March 18, 2014, Opexa
Therapeutics, Inc.'s (Opexa) stock went up by 14.81%, to close at
$2.17. For the past five-day trading
period, Opexa Therapeutics' shares advanced 17.93%, compared to the
Nasdaq Composite which gained 0.61% during the same trading period.
The full analyst notes on Opexa Therapeutics, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03212014/OPXA/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review